ScripTORL BioTherapeutics LLC is aiming for its latest fundraise to take it past the regulatory finish line with TORL-1-23, which it calls a first-in-class antibody-drug conjugate (ADC) targeting Claudin
ScripVenture capital firms that support biotechnology companies are raising billions of dollars to make new investments in 2023, but so far this year VC investors have invested conservatively in drug devel